tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Mounjaro, Zepbound Lowers Risk of

Conclusion Retatrutide represents a groundbreaking advancement in obesity and T2D management, with phase 2 trials demonstrating unprecedented weight loss (up to 24.2% at 48 weeks) and glycemic control (HbA1c reductions up to 2.0%)

The results were also similar for people with and without a diagnosis of obesity

In summary, GLP-1RAs provide substantial weight loss and cardiometabolic benefits but may compromise skeletal muscle integrity, whereas exercise supports muscle maintenance and functional health, though its effect on weight reduction is typically modest compared with pharmacotherapy

Collagen peptides are generally recognized as safe (GRAS) food ingredients

The pivotal trials leading to FDA approval demonstrated reductions in visceral adipose tissue of approximately 15 to 20% over 26 weeks in HIV lipodystrophy patients, with continued reduction at 52 weeks